October 26, 2017 10:20 AM EDTUpdated 04:49 PM

Tesaro wins FDA OK for an IV version of chemo drug, launches discovery deal with Evotec

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation